

EXECUTIVE TEAM

Magnus Medical, Inc.

Christian Gormsen

President and Chief Executive Officer

Member, Board of Directors

Christian Gormsen joined Magnus Medical in January 2024 as president, chief executive officer, and a member of its board of directors, bringing over two decades of operational leadership experience across diverse continents and industries. Before joining Magnus, Mr. Gormsen was president and CEO of Eargo, a medical device developer of innovative hearing aids, where he orchestrated the company's rise from commercialization in 2017 to surpassing a +\$100 million run rate by 2021, alongside securing over \$500 million in capital across five private fund raises, and an IPO in 2020. Mr. Gormsen also served as a member of Eargo's board of directors for nine years. His career tenure spans strategic roles such as senior vice president at GN Group, a global leader in intelligent audio solutions, where he oversaw operations across 14 countries and managed a revenue stream exceeding \$150 million with a 30% EBITA. During his stewardship, he coordinated a comprehensive restructuring across Europe, driving local execution while reducing costs and expanding market share. Previously, Mr. Gormsen was chief operating officer of Sterling Air, where he optimized operational efficiency to establish Scandinavia's leading low-cost carrier. He began his career in investment banking before transitioning to McKinsey & Company.

Mr. Gormsen received a Bachelor of Science in Economics and a Master of Science in Finance and Accounting from the Copenhagen Business School.

Brandon Bentzley, M.D., Ph.D.

Co-founder, Chief Scientific Officer

Head of Research and Development

Brandon Bentzley, M.D., Ph.D., is co-founder and chief scientific officer of Magnus Medical. His interest in neuroscience led him to begin the Medical Scientist Training Program at the Medical University of South Carolina (MUSC), which is the birthplace of clinical transcranial magnetic stimulation (TMS) for the treatment of neuropsychiatric disorders. At MUSC, he completed his dissertation research with Gary Aston-Jones, Ph.D., studying the behavioral economics and neuroeconomics of substance use disorders. Simultaneously, he conducted clinical research on buprenorphine maintenance therapy, focusing on how patient perspectives influence treatment. He completed his residency in adult psychiatry and his postdoctoral training at Stanford University, where he focused on the development of SAINT technology. Dr. Bentzley has published articles in high-impact peer-reviewed

journals, including *Brain*, *American Journal of Psychiatry*, *Molecular Psychiatry*, *Biological Psychiatry*, *Journal of Neuroscience*, *Journal of the American Medical Association Network Open*, and *Proceedings of the National Academy of Sciences of the United States of America*.

In parallel with his clinical work, Dr. Bentzley has over 15 years of experience in developing advanced automated systems that range from plasma reactors used in variable gravity experiments at NASA to high-powered magnetically confined plasma reactors at Princeton University. He has developed and built a highly advanced neuro-behavioral recording system, which is currently in full-time use at the Malenka Lab in the Department of Psychiatry at Stanford Medicine.

Dr. Bentzley received a Bachelor of Science in Physics from The College of New Jersey and his M.D. and Ph.D. from MUSC. His academic appointments include Clinical Assistant Professor in Psychiatry and Behavioral Sciences at Stanford University School of Medicine. His areas of clinical focus are treatment-resistant depression, substance abuse disorders, and suicidality.

Vikram Lamba, MBA **Chief Financial Officer**

Vikram Lamba joined Magnus Medical in September 2024 as chief financial officer with responsibilities for operations and business development, bringing over three decades of global healthcare experience and an established track record of success with large pharmaceutical companies and a range of startup entities.

Mr. Lamba began his healthcare career at Bayer AG in Canada, Germany, and the U.S., where he held executive roles in M&A and as a divisional chief financial officer for over eight years. Before joining Magnus, Mr. Lamba most recently was chief financial officer and head of business development at ImmPACT Bio USA, Inc., a cell therapy company focused on oncology and autoimmune diseases. His prior executive positions include founding chief financial officer at Civica, Inc., chief executive officer and board member at Zosano Pharma Corporation, and vice president of corporate development at AMO, Inc., among others.

Mr. Lamba received his undergraduate degree in mechanical engineering in India and his MBA from the Asian Institute of Management, where he spent his final year as an exchange student at The Wharton School of the University of Pennsylvania.

Huyen Duong **Head of Clinical, Quality and Regulatory**

Huyen Duong joined Magnus Medical in May 2023 as vice president of regulatory affairs and quality assurance, and in January 2024, her responsibilities expanded to include clinical

affairs. Ms. Duong has over 20 years of experience in leading regulatory, quality, and clinical organizations in a global environment, working with novel Class II and Class III medical devices from world-class organizations. Before joining Magnus, she was vice president of regulatory, quality and clinical affairs at Nesos Corporation, a startup where she was responsible for defining regulatory and clinical strategies to support global commercialization of Nesos' non-invasive neuromodulation platform for the treatment of migraines, rheumatoid arthritis, and postpartum depression. Previously, Ms. Duong was the senior director of regulatory affairs and clinical operations for Nevro Corporation, where she supported pre- and post-market regulatory activities and the conduct of more than 20 new and ongoing clinical investigations while managing clinical operational processes to guarantee compliance with the U.S. FDA and international requirements for clinical trials. She has also held senior management positions in regulatory affairs at Boston Neuromodulation and Bausch and Lomb.

Ms. Duong earned a Bachelor of Science in Biological Sciences from the University of California, Irvine.

JoLynn M. Short
Head of Commercialization

JoLynn M. Short is head of commercialization for Magnus Medical, bringing 17 years of experience in revenue-generating processes and a deep understanding of how data supports the achievement of revenue targets. Prior to joining Magnus, she accelerated growth for 15 years at iRhythm Technologies, a leading digital health cardiac monitoring company. Promoted on several occasions, Ms. Short was most recently vice president of strategy and growth at iRhythm, where she led the team responsible for developing and coordinating worldwide growth strategies. As area vice president for the Central U.S., she launched Zio AT, a mobile cardiac telemetry monitoring service, driving 35% year-over-year growth in the area.

Ms. Short earned a Bachelor of Science in Political Science from the University of Northern Iowa.

Joost de Schutter
Head of Corporate Function

Joost de Schutter is head of corporate function for Magnus Medical, contributing over 25 years of experience in healthcare technology and life sciences for both Fortune 500 companies and startups. Most recently, Mr. de Schutter was vice president of finance for HeartFlow, where he successfully guided the company through its transition to public company readiness. Previously, he was vice president of finance for Thermo Fisher Scientific's Clinical Diagnostics Division, where he partnered with the global division's

executive team to drive revenue growth and margin expansion while managing all aspects of the finance function. His previous tenures also include multiple senior management positions, including vice president, corporate controller for Prysm, consulting CFO for RenovoRX, an early-stage medical device start-up, and various finance leadership positions at Philips Healthcare.

Mr. de Schutter earned a Bachelor of Science in Business Economics from Erasmus University Rotterdam, and an international Executive Master of Finance and Control (iEMFC) from both the University of Maastricht, The Netherlands, and Washington University, St. Louis, receiving the Certified Controller title.

Romain Moreau-Gobard
Head of Software Engineering

Romain Moreau-Gobard joined Magnus Medical as vice president of software engineering. He contributes over 20 years of experience in the development of advanced medical imaging software for both startups and established multinational companies. Before joining Magnus, he was vice president of software engineering for Advanced Scanners, where he led the development of 3D reconstruction and imaging algorithms for a novel structured light scanner for brain and spine imaging. Prior to this, Mr. Moreau-Gobard led software engineering teams at HeartFlow, where he designed a novel SAMD (software as a medical device) product to determine the fractional flow reserve from cardiac computed tomography (CT) scans, allowing entirely non-invasive detection and diagnosis of heart disease. HeartFlow's software received U.S. Food & Drug Administration (FDA) clearance in 2014, and in 2021, the company announced it would go public with a valuation of \$2.4 billion. Mr. Moreau-Gobard has also held engineering leadership roles at Siemens Medical and Siemens Corp. Technology.

Mr. Moreau-Gobard received a Master of Science in Artificial Intelligence from EPITA, the School of Engineering and Computer Science in Paris, France, and a Master of Science in Management of Information Systems from Stevens Institute of Technology. He currently holds 15 U.S. and international patents.

#